APREA THERAPEUTICS, INC.

(APRE)
SummaryQuotesChartsNewsCompanyFinancials 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

APREA THERAPEUTICS, INC. : Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)

01/13/2022 | 08:03am EDT

Item 2.02 Results of Operations and Financial Condition

As discussed below, in connection with participation in the 40th Annual J.P. Morgan Healthcare Conference, Aprea Therapeutics, Inc. (the 'Company") updated its corporate presentation to include disclosure that the Company expects cash and cash equivalents of $50.0 million to $55.0 million (unaudited) as of December 31, 2021.

Because the Company's consolidated financial statements for the year ended December 31, 2021 have not yet been finalized or audited, the preliminary statement of the Company's cash and cash equivalents as of December 31, 2021 in this Item 2.02 is subject to change, and the Company's actual cash and cash equivalents as of December 31, 2021 may differ materially from this preliminary estimate. Accordingly, you should not place undue reliance on this preliminary estimate.

Item 7.01 Regulation FD Disclosure

Beginning on January 13, 2022, the Company will participate in the 40th Annual J.P. Morgan Healthcare Conference. The Company has updated its corporate presentation that it intends to use in connection with its presentation on Thursday January 13, 2022 at 11:15 p.m. Eastern Time in meetings with investors.

A copy of the Company's corporate presentation is attached hereto as Exhibit 99.1 and is hereby incorporated by reference herein.

The information contained in Item 2.02 and Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1, is furnished pursuant to Item 2.02 and Item 7.01 of Form 8-K and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, except as expressly stated by specific reference in such filing.

Item 9.01. Financial Statements and Exhibits.





(d)     Exhibits.



Exhibit
Number                                  Description
  99.1       Aprea Therapeutics, Inc. Presentation

  104      The cover page from this Current Report on Form 8-K, formatted as
           Inline XBRL

© Edgar Online, source Glimpses

All news about APREA THERAPEUTICS, INC.
05/25Berenberg Bank Adjusts Aprea Therapeutics' Price Target to $1 From $4, Maintains Hold R..
MT
05/17APREA THERAPEUTICS, INC. : Entry into a Material Definitive Agreement, Completion of Acqui..
AQ
05/17APREA THERAPEUTICS, INC.(NASDAQGS : APRE) added to NASDAQ Composite Index
CI
05/16APREA THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition a..
AQ
05/16TRANSCRIPT : Aprea Therapeutics, Inc. - Special Call
CI
05/16APREA THERAPEUTICS, INC. : Results of Operations and Financial Condition, Regulation FD Di..
AQ
05/16Aprea Therapeutics Announces Acquisition of Atrin Pharmaceuticals Inc. and Reports Firs..
GL
05/16Aprea Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31,..
CI
05/16APREA THERAPEUTICS, INC.(NASDAQGS : APRE) dropped from NASDAQ Composite Index
CI
05/16ATRIN PHARMACEUTICALS LLC ACQUIRED A : APRE) in a reverse merger transaction.
CI
More news
Analyst Recommendations on APREA THERAPEUTICS, INC.
More recommendations
Financials (USD)
Sales
Net income
Net Debt
P/E ratio
Yield
Capitalization 15,2 M 15,2 M -
EV / Sales -1
EV / Sales 0
Nbr of Employees -
Free-Float 90,0%
Chart APREA THERAPEUTICS, INC.
Duration : Period :
Aprea Therapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends APREA THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Managers and Directors
Christian S. Schade Chairman, President & Chief Executive Officer
Scott M. Coiante Chief Financial Officer, Secretary & Senior VP
Eyal C. Attar Chief Medical Officer & Senior Vice President
Lars Abrahmsén Chief Scientific Officer & Senior Vice President
Bernd Robert Seizinger Independent Director
Sector and Competitors
1st jan.Capi. (M$)
APREA THERAPEUTICS, INC.-77.00%15
MODERNA, INC.-48.48%52 528
LONZA GROUP AG-27.13%42 896
IQVIA HOLDINGS INC.-27.93%38 232
SEAGEN INC.-11.73%24 569
ICON PUBLIC LIMITED COMPANY-31.56%17 581